obJective The authors sought to determine whether flow diversion with the Pipeline Embolization Device (PED) can approximate microsurgical decompression in restoring function after cranial neuropathy following carotid artery aneurysms. methods This multiinstitutional retrospective study involved 45 patients treated with PED across the United States. All patients included presented between November 2009 and October 2013 with cranial neuropathy (cranial nerves [CNs] II, III, IV, and VI) due to intracranial aneurysm. Outcome analysis included clinical and procedural variables at the time of treatment as well as at the latest clinical and radiographic follow-up. results Twenty-six aneurysms (57.8%) were located in the cavernous segment, while 6 (13.3%) were in the clinoid segment, and 13 (28.9%) were in the ophthalmic segment of the internal carotid artery. The average aneurysm size was 18.6 mm (range 4-35 mm), and the average number of flow diverters placed per patient was 1.2. Thirty-eight patients had available information regarding duration of cranial neuropathy prior to treatment. Eleven patients (28.9%) were treated within 1 month of symptom onset, while 27 (71.1%) were treated after 1 month of symptoms. The overall rate of cranial neuropathy improvement for all patients was 66.7%. The CN deficits resolved in 19 patients (42.2%), improved in 11 (24.4%), were unchanged in 14 (31.1%), and worsened in 1 (2.2%). Over time, the rate of cranial neuropathy improvement was 33.3% (15/45), 68.8% (22/32), and 81.0% (17/21) at less than 6, 6, and 12 months, respectively. At last follow-up, 60% of patients in the isolated CN II group had improvement, while in the CN III, IV, or VI group, 85.7% had improved. Moreover, 100% (11/11) of patients experienced improvement if they were treated within 1 month of symptom onset, whereas 44.4% (12/27) experienced improvement if they treated after 1 month of symptom onset; 70.4% (19/27) of those with partial deficits improved compared with 30% (3/10) of those with complete deficits. coNclusioNs Cranial neuropathy caused by cerebral aneurysm responds similarly when the aneurysm is treated with the PED compared with open surgery and coil embolization. Lower morbidity and higher occlusion rates obtained with the PED may suggest it as treatment of choice for some of these lesions. Time to treatment is an important consideration regardless of treatment modality.
M icrosurgery remains the gold standard for decompression of cranial nerves (CNs) affected by aneurysmal mass effect. Over the past 2 decades, coil embolization has gained rapid acceptance as a viable alternative. For the treatment of large unruptured aneurysms of the proximal internal carotid artery, flow diversion has grown in popularity as an alternative to both microsurgery and coil embolization. Cranial nerve compression is not an uncommon presenting symptom for these aneurysms. For cavernous aneurysms, the presenting symptom is diplopia in about 65% of patients, while decreased visual acuity affects approximately 16% of patients. 30 The question of whether endovascular flow diversion can approximate microsurgical decompression in restoring function in cranial neuropathy remains unanswered. To our knowledge, there have been no studies focusing on the results of cranial neuropathy after Pipeline Embolization Device (PED; Covidien) flow diversion. We set out to review this subject in the following multiinstitutional study.
methods
This study was approved by each participating institution's review board. The medical records of patients presenting with cranial neuropathy (CNs II, III, IV, and VI) due to cerebral aneurysm treated with flow diversion between November 2009 and October 2013 were retrospectively reviewed. Ten institutions from North America, led by the Endovascular Neurosurgery Research Group, contributed patient data. Antiplatelet agents were used for all patients in the pre-and postoperative period; however, the antiplatelet agent and dosage varied per each institution's standard. All outcomes were assessed during routine office visits and were based on the clinical judgment of each physician at the treating institutions. All patients were treated using the PED. The PED was sized according to standard protocol to be larger than the maximum diameter of the target vessel to ensure good wall apposition. Additional devices were deployed at the surgeon's discretion to increase stasis within the aneurysm or to ensure complete coverage of a lesion if a longer construct was required.
Patient demographics, presentation deficit, duration of deficit prior to treatment, aneurysm demographics, number of flow diverters used, presence/absence of coils, cranial neuropathy outcome (resolved, improved, unchanged, or worse), clinical complications, and radiographic outcome (Raymond classification
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) were recorded. Subanalyses were performed for CN II and CNs III, IV, and VI. Cranial nerves III, IV, and VI were grouped together because of their similar function. Some patients involved in the study were also reported on in the Pipeline for Uncoilable or Failed Aneurysms Study. 
statistical analysis
The statistical analysis of this study was largely descriptive. Descriptive statistics such as mean and percentage were used to characterize the data. Univariate analysis was performed to understand which factors were associated with better outcome. Factors that were studied included duration of the deficit prior to treatment, complete palsy, use of coils, follow-up time, Raymond classification (complete occlusion vs partial occlusion), and aneurysm size. Statistically significant difference in outcomes based on treatment parameters was determined by Fisher's exact test. A p value of < 0.05 was determined to be statistically significant. Odds ratios were computed when possible with their corresponding 95% confidence intervals. Statistical analysis was performed using JMP version 10.0.0 (SAS Institute).
results
Forty-five patients met inclusion criteria for the study, representing 45 treated aneurysms of the proximal intracranial internal carotid artery. The demographic information for the patients is included in Table 1 . There were 42 females (93%) and 3 males (7%). The mean age was 64.7 years (range 33-89 years). Of the 45 aneurysms, 26 (57.8%) were located in the cavernous segment, while 6 (13.3%) were in the clinoid segment, and 13 (28.9%) were in the ophthalmic segment. The average aneurysm size was 18.6 mm (range 4-35 mm). There were 19 aneurysms larger than 20 mm, 19 aneurysms between 10 and 20 mm, and 7 aneurysms smaller than 10 mm. The average number of flow diverters placed per patient was 1.2. Thirty-eight patients had available information regarding duration of cranial neuropathy prior to treatment. Eleven (28.9%) were treated within 1 month of symptom onset, while 27 (71.1%) were treated after having symptoms for 1 month. The treatment information is summarized in Table 2 . The average follow-up was 8.4 months (range 0.1-21.5 months). Forty patients had available follow-up imaging. Radiographically, 26 aneurysms (65%) were completely occluded, 9 (22.5%) had a neck residual, and 5 (12.5%) had some residual dome filling at last follow-up. Thirteen patients had 12-month follow-up imaging, with 11 (84.6%) showing complete occlusion and the remaining 2 (15.4%) showing a neck remnant. The 30-day morbidity was 17.8%, including 3 ischemic strokes, 2 hemorrhagic strokes, 1 gastrointestinal bleed, 1 myocardial infarction, and 1 new-onset cranial neuropathy. There was 1 ischemic stroke with lasting morbidity, making the 30-day rate of major stroke or death 2.2%.
At last follow-up, the overall rate of cranial neuropathy improvement for all patients was 66.7% (30/45). Cranial nerve deficits resolved in 19 patients (42.2%), improved in 11 (24.4%), were unchanged in 14 (31.1%), and worsened in 1 (2.2%). The length of follow-up varied for each patient. Over time, the rate of cranial neuropathy improvement was 33.3% (15/45), 68.8% (22/32), and 81.0% (17/21) at less than 6, 6, and 12 months, respectively. At less than 6 months, 15.6% (7/45) had worsening of their cranial neuropathy. Between 6 and 12 months, the number decreased to 3.1% (1/32) and 4.8% (1/21), respectively. These data are summarized as a chart in Fig. 1 . At 12 months, there were 5 patients with isolated CN II deficits and 14 patients with CN III, IV, or VI (or some combination) deficits. At last follow-up, 60% of patients with CN II deficits had improved, whereas 85.7% of those with CN III, IV, or VI deficits had improved. These results, shown over time, are summarized in Fig. 2 .
Thirty-eight patients had a known duration of symptoms prior to treatment. At last follow-up, 100% (11/11) of patients who were treated within 1 month of symptom onset experienced improvement, while 44.4% (12/27) . These findings are summarized in Table 3 .
discussion
Our study demonstrates a comparable rate of cranial neuropathy improvement when using flow diversion compared with rates reported in the literature for both microsurgical and endovascular techniques. The bulk of available data involve CNs II and III. A literature search for series of 5 or more patients reporting on resolution of CNs II and III after surgical and endovascular intervention of cerebral aneurysm was performed. Tables 4 and 5 summarize the literature for CN II and III deficit outcomes, respectively. The improvement rates for CN II deficits range between 50% and 100% (mean 68.6%) for microsurgery and between 37.5% and 60% (mean 46.2%) for coiling. Our series found an improvement rate of 60% at 12 months for those patients with CN II neuropathy, placing flow diversion slightly behind microsurgery and ahead of coil embolization. The improvement rates for CN III deficits range between 77% and 100% (mean 93.6%) for microsurgery and between 80% and 100% (mean 92.2%) for coil embolization. In the present series, we found an 85% improvement rate for deficits CNs III, IV, and VI at 12 months, placing flow diversion slightly behind both microsurgery and coil embolization.
As indicated in Tables 4 and 5 , the rates of cranial neuropathy recovery after coiling or surgical clipping of cerebral aneurysms vary widely in published literature. There are a few retrospective studies that analyze predictors of improvement aside from method of treatment. Most of these studies deal with cranial neuropathy due to posterior communicating artery aneurysms. Factors considered are age, duration of symptoms prior to treatment, cranial neuropathy associated with subarachnoid hemorrhage, and cardiovascular risk factors (tobacco use, obesity, dyslipidemia, hypertension, and diabetes). Stiebel-Kalish et al.
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reported on 11 patients treated with coiling and noted that age and microvascular risk factors were observed more often in those cases with residual cranial nerve palsy. Ahn et al.
1 reported on 10 patients who were treated with coiling and 7 patients who underwent microsurgical clipping. In the coiling group, older age, presence of diabetes, complete third nerve palsy at presentation, and delayed treatment were associated with poor prognosis in recovery, whereas in the clipping group, only older age was related to decreased cranial nerve recovery. On the other hand, Kassis et al. 18 reported outcomes for 20 patients, noting that early management (within 7 days of cranial nerve palsy onset) and clinical presentation with subarachnoid hemorrhage influenced recovery, but cardiovascular risk had no effect. Recently, Chalouhi et al. 3 observed recovery of nearly 90% of CN III deficits after endovascular treatment in 37 patients, and partial deficit at presentation was the only statistically significant predictor of complete recovery. Due to the design of previously published studies, it is unclear whether there was an association of recovery prognosis with factors other than the method of treatment, but time to treatment and CN deficit at presentation are consistently reported.
In the present study, we tested 4 parameters in our secondary analysis: time from onset of neuropathy to treatment, presence of coils, aneurysm size, partial or complete cranial neuropathy, and age. The only factor that reached statistical significance was time from onset of neuropathy to treatment (< 1 month); all 11 patients had improvement in their deficit. Presence of partial versus complete neuropathy at presentation nearly reached statistical significance (p = 0.56, OR 5.54), which is consistent with prior literature, indicating that the degree of deficit has prognostic value regardless of treatment technique. 1,3 Interestingly, the absence or presence of coils had almost no effect on the improvement rate (p = 1, OR 1.2), which supports the theory in coiling literature that the cranial neuropathy depends less on mass effect than it does on the pulsatility of the aneurysm sac.
It is important to note that in 15% of our patients, cranial neuropathy worsened in the short term after placement of a flow diverter. This number decreased to 4.8% (representing 1 patient) by 12 months. This is important to note for the counseling of patients if flow diversion is to be used.
This study is limited by its retrospective nature as well as the relatively small sample size. Data were extracted from multiple institutions and therefore depend on each institution's records. Formal neuroophthalmological testing was not available for many patients. Another confounding factor in our study is that we examined all recovery of function of all cranial nerves related to visual function (CNs II, III, IV, and VI). CNs III, IV, and VI were grouped together because of their similar function. It is possible that some of these nerves are more likely to improve than others.
The average follow-up time was 8.4 months. In a disease that clearly improves with time, it would be helpful to have longer follow-up times.
conclusions
Cranial neuropathy caused by cerebral aneurysm responds similarly when the aneurysm is treated with PED in comparison with open surgery and coil embolization. Lower morbidity and higher occlusion rates obtained with the PED may suggest it as treatment of choice for some of these lesions. Time to treatment is an important consideration regardless of treatment modality. A prospective study with formal pre-and posttreatment ophthalmological examinations is warranted to verify these findings.
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